Government launches subsidised Continuous Glucose Monitoring for all Australians living with type 1 diabetes from 1 July 2022 - AMSL Diabetes


Government launches subsidised Continuous Glucose Monitoring for all Australians living with type 1 diabetes from 1 July 2022

1 July 2022 – Dexcom and AMSL Diabetes welcome the recent Continuous Glucose Monitoring (CGM) subsidy expansion, allowing thousands more Australians with type 1 diabetes access to subsidised CGM products like Dexcom G6 CGM.

  • Existing users who were previously eligible for the CGM Subsidy Initiative will be able to continue to access fully subsidised CGM products
  • Individuals who are now able to access subsidised CGM from the 1st July 2022, will be able to access subsidised CGM Dexcom G6 products through a co-payment of only $32.10

EXISTING active Dexcom G6 customers (that is, customers who have purchased Dexcom G6 directly from AMSL Diabetes between 1 January 2022 and 1 June 2022, and will be continuing with Dexcom G6 through the subsidy initiative) will be able to apply for subsidised Dexcom G6 via a streamlined process, developed by NDSS in a bid to ease the process for existing customers and the healthcare professionals that support them. Existing active customers will need to follow the steps below.

1. Go to ndss.com.au/cgm-expansion-form/
2. Validate your NDSS registration details using your last name and NDSS number
3. Complete the online form to confirm your contact details and the CGM device you are currently using AND consent to the information you have provided being validated with the supplier (AMSL Diabetes) of your current CGM
4. NDSS will contact the supplier to confirm your validation
5. When validated, you will receive a notification from NDSS. Following this, you can access subsidised CGM from your local NDSS Access Point/Pharmacy

However, individuals new to CGM or Dexcom G6* specifically will need to follow a different application process, see below.

1. Review the eligibility criteria available at ndss.com.au/about-the-ndss/cgm-initiative/ and speak to your HCP to see is Dexcom is right for them
2. Complete the relevant Access Form found at ndss.com.au/about-the-ndss/cgm-initiative/. This needs to be prepared and signed by your HCP
3. Diabetes Australia will contact you to confirm eligibility for access to subsidised CGM products
4. The initial Dexcom kit will be sent to your HCP for the Dexcom start
5. Following on from here, you can order and collect supplies from your local NDSS Access Point/Pharmacy

We thank all the individuals and organisations who have supported and worked for improved access to diabetes technologies for the diabetes community. Through tireless advocacy and education, they have worked toward ensuring more individuals will be able to benefit from these technologies.

For more information on the NDSS CGM subsidy expansion, head to product.amsl.com.au/cgmsubsidy. Alternatively, if you’d like more information on this announcement, please email us at diabetes@amsl.com.au.


About AMSL Diabetes

AMSL Diabetes is dedicated to helping people live well with diabetes. For over 20 years, AMSL Diabetes has given thousands of people the tools and support they need to improve their quality of life. AMSL Diabetes provides a range of diabetes products to individuals living with diabetes and the healthcare professionals that support them including t:slim X2 Insulin Pumps, Dexcom CGM Systems and other diabetes accessories. For more information, visit amsldiabetes.com.au

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit dexcom.com

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE. Read the warnings available on https://amsldiabetes.com.au/resources before purchasing. Consult your healthcare professional to see if this product is right for you.

*Note: prior to receiving subsidised Dexcom G6 via this subsidy expansion, we ask that you check your mobile device is compatible as a display device at http://dexcom.com/en-AU/compatibility

AMSL is a subsidiary of Dexcom.

“Effective immediately, all Australians living with type 1 diabetes will be able to access subsidised CGM like Dexcom G6 for only $32.10 per month.”

Government launches subsidised Continuous Glucose Monitoring for all Australians living with type 1 diabetes from 1 July 2022

Stay informed with AMSL Diabetes

Now you can get all the latest news and updates of our products, events and resources right into your inbox.

Something went wrong. Please try again later!

Send AMSL Diabetes a message

We are always happy to help, send us a message or enquiry

Back to top